2-(4-butoxyphenyl)-5-nitro-1H-benzimidazole | 1416273-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(4-butoxyphenyl)-5-nitro-1H-benzimidazole
• 英文别名: 2-(4-butoxyphenyl)-6-nitro-1H-benzimidazole
• CAS: 1416273-13-6
• 化学式: C₁₇H₁₇N₃O₃
• 分子量: 311.34
• InChiKey: PUVYUOWJNJWOLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  83.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-丁氧基苯甲醛 在 sodium metabisulfite 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-butoxyphenyl)-5-nitro-1H-benzimidazole
  参考文献：
  名称：

  Benzimidazole derivatives: synthesis, leishmanicidal effectiveness, and molecular docking studies

  摘要：

  Leishmanolysin GP63 is a zinc metalloprotease, expressed at the surface of Leishmania promastigotes. Studies on this protein are hindered as only a limited number of effective non-toxic inhibitors of this drug target are known. Present study describes the identification of a variety of 2-aryl- and 5-nitro-2-arylbenzimidazoles as new GP63 inhibitors. All the compounds were tested for in vitro activity against the promastigote form of Leishmania major and showed very good activity. 2-(Thiophen-2-yl)-1H-benzimidazole (19) and 2-(1H-indol-3-yl)-5-nitro-1H-benzimidazole (34) with IC50 value of 0.62 mu g/mL were identified as lead of this library. Molecular docking studies were performed on binding site of GP63 to study the binding mode of compounds. The results of both in vitro and in silico studies clearly indicated that benzimidazoles may serve as new drug candidates in the combat against leishmaniasis.

  DOI：

  10.1007/s00044-012-0375-5

文献信息

• Benzimidazole derivatives: synthesis, leishmanicidal effectiveness, and molecular docking studies
  作者：Awais Shaukat、Hira M. Mirza、Amna H. Ansari、Masoom Yasinzai、Sohail Z. Zaidi、Sana Dilshad、Farzana L. Ansari

  DOI：10.1007/s00044-012-0375-5

  日期：2013.8

  Leishmanolysin GP63 is a zinc metalloprotease, expressed at the surface of Leishmania promastigotes. Studies on this protein are hindered as only a limited number of effective non-toxic inhibitors of this drug target are known. Present study describes the identification of a variety of 2-aryl- and 5-nitro-2-arylbenzimidazoles as new GP63 inhibitors. All the compounds were tested for in vitro activity against the promastigote form of Leishmania major and showed very good activity. 2-(Thiophen-2-yl)-1H-benzimidazole (19) and 2-(1H-indol-3-yl)-5-nitro-1H-benzimidazole (34) with IC50 value of 0.62 mu g/mL were identified as lead of this library. Molecular docking studies were performed on binding site of GP63 to study the binding mode of compounds. The results of both in vitro and in silico studies clearly indicated that benzimidazoles may serve as new drug candidates in the combat against leishmaniasis.